orserdu
stemline therapeutics b.v. - elacestrant - bröst-neoplasmer - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
nolvadex 10 mg tablett
astrazeneca ab - tamoxifencitrat - tablett - 10 mg - laktosmonohydrat hjälpämne; tamoxifencitrat 15,2 mg aktiv substans - tamoxifen
tamoxifen orifarm 10 mg tablett
orifarm generics a/s - tamoxifencitrat - tablett - 10 mg - laktosmonohydrat hjälpämne; tamoxifencitrat 15,2 mg aktiv substans - tamoxifen
nolvadex 20 mg tablett
astrazeneca ab - tamoxifencitrat - tablett - 20 mg - laktosmonohydrat hjälpämne; tamoxifencitrat 30,4 mg aktiv substans - tamoxifen
tamoxifen mylan 20 mg tablett
mylan ab - tamoxifencitrat - tablett - 20 mg - tamoxifencitrat 30,4 mg aktiv substans; mannitol hjälpämne - tamoxifen
tamoxifen sandoz 20 mg filmdragerad tablett
sandoz a/s - tamoxifencitrat - filmdragerad tablett - 20 mg - tamoxifencitrat 30,4 mg aktiv substans; laktosmonohydrat hjälpämne - tamoxifen
tamoxifen orifarm 20 mg tablett
orifarm generics a/s - tamoxifencitrat - tablett - 20 mg - laktosmonohydrat hjälpämne; tamoxifencitrat 30,4 mg aktiv substans - tamoxifen
tamoxifen orifarm 30 mg tablett
orifarm generics a/s - tamoxifencitrat - tablett - 30 mg - laktosmonohydrat hjälpämne; tamoxifencitrat 45,6 mg aktiv substans - tamoxifen
fareston
orion corporation - toremifen - bröst-neoplasmer - endokrin terapi - första radhormonbehandling av hormonberoende metastatisk bröstcancer hos postmenopausala patienter. fareston rekommenderas inte för patienter med östrogen receptor-negativ tumörer.
faslodex
astrazeneca ab - fulvestrant - bröst-neoplasmer - endokrin terapi, anti-östrogener - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. i pre - eller perimenopausala kvinnor, kombinationsbehandling med palbociclib bör kombineras med en luteinizing hormone releasing hormone (gnrh) agonist.